These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 32354280)

  • 1. Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial.
    Ferreira JP; Eschalier R; Duarte K; Damman K; Gustafsson F; Schou M; Girerd N; Fay R; Tala S; Pitt B; Zannad F; Rossignol P
    Circ Heart Fail; 2020 May; 13(5):e006597. PubMed ID: 32354280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
    Ter Maaten JM; Martens P; Damman K; Dickstein K; Ponikowski P; Lang CC; Ng LL; Anker SD; Samani NJ; Filippatos G; Cleland JG; Zannad F; Hillege HL; van Veldhuisen DJ; Metra M; Voors AA; Mullens W
    Clin Res Cardiol; 2020 Aug; 109(8):1048-1059. PubMed ID: 32002631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C; Ahmed A; Fay R; Angioi M; Filippatos G; Vincent J; Pitt B; Zannad F;
    Eur J Heart Fail; 2009 Nov; 11(11):1099-105. PubMed ID: 19875410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diuretic therapy in acute heart failure].
    Trullàs JC; Morales-Rull JL; Formiga F
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():36-41. PubMed ID: 24930082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
    Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Mullens W
    Am J Cardiol; 2017 Jul; 120(2):267-273. PubMed ID: 28532770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of short-acting loop diuretic doses and cardiac sympathetic nerve abnormalities on outcomes of patients with reduced left ventricular function.
    Onitsuka H; Koyama S; Ideguchi T; Ishikawa T; Kitamura K; Nagamachi S
    Medicine (Baltimore); 2019 Feb; 98(8):e14657. PubMed ID: 30813209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.
    Coiro S; Girerd N; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Lamiral Z; Rossignol P; Zannad F
    Clin Res Cardiol; 2021 Aug; 110(8):1308-1320. PubMed ID: 33956209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial.
    Ferreira JP; Rossello X; Pitt B; Rossignol P; Zannad F
    Clin Cardiol; 2019 Nov; 42(11):1106-1112. PubMed ID: 31482613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of eplerenone on clinical stability of Japanese patients with acute heart failure.
    Kobayashi M; Ferreira JP; Matsue Y; Chikamori T; Ito S; Asakura M; Yamashina A; Kitakaze M
    Int J Cardiol; 2023 Mar; 374():73-78. PubMed ID: 36586516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
    Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ
    Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
    Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazide diuretics versus loop diuretics in stage 3-5 CKD: impact on cardiorenal outcomes.
    Sung LC; Chiu HW; Yu SM; Tsou LL; Hsu YH; Wu MS; Lin CL; Tsai FJ; Chou CL
    Postgrad Med; 2024 Sep; 136(7):738-748. PubMed ID: 39189768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.